解放军医学杂志2024，Vol.49Issue(7)：848-854,7.DOI:10.11855/j.issn.0577-7402.0994.2024.0104
肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展
Research progress of tumor autoantibodies and CT artificial intelligence in early diagnosis of NSCLC
摘要
Abstract
Non-small cell lung cancer(NSCLC)is one of the most prevalent and deadly malignant tumors in the world.In recent years,artificial intelligence(AI)in computed tomography(CT)has harnessed the power of big data to automatically extract and learn imaging features,thereby assisting radiologists in reducing the workload and missed diagnosis rate of pulmonary nodules.An ELISA kit for detecting seven lung cancer autoantibodies(p53,SOX2,PGP9.5,CAGE,MAGE-A1,GAGE7,and GBU4-5)has been clinically implemented in China,showing high specificity in the early screening of NSCLC.Additionally,other liquid biopsy techniques such as circulating tumor DNA(ctDNA)methylation markers are also continually being explored.However,existing methods for the early diagnosis of lung cancer all have their limitations,and optimizing their combination or establishing diagnostic models has become a trend.This review summarizes the research progress and value of the seven lung cancer autoantibodies and CT AI in the early diagnosis of NSCLC,with the aim of providing a reference for their combined use in the early diagnosis of lung cancer in Chinese population.关键词
非小细胞肺癌/自身抗体/人工智能/肺结节/早期诊断Key words
non-small-cell lung carcinoma/autoantibodies/artificial intelligence/pulmonary nodules/early diagnosis分类
医药卫生引用本文复制引用
王晶,翟成凯..肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展[J].解放军医学杂志,2024,49(7):848-854,7.基金项目
This work was supported by the Scientific and Technological Project of Xinxiang City(GG2019033) 新乡市科技攻关计划项目(GG2019033) （GG2019033）
